Sanofi has made several strategic strides in the biotech sector. One significant move is it's $25 million investment in
Adagene, strengthening the collaboration. A number of studies hold promise for groundbreaking advances:
Dupilumab showing potential as a game changer for
pediatric asthma and
atopic dermatitis;
Tolebrutinib being slated as a potential game changer for
multiple sclerosis, and a
Phase 3 study on
Riliprubart possibly changing the game for
CIDP treatment. Sanofi has also entered a €545M deal to explore
Formation's JAK/SYK inhibitor. It's other innovation includes
AI-powered manufacturing,
digital transformation and environmental sustainability initiatives. Sanofi plans to acquire US biopharma group,
Blueprint Medicines and
Vigil Neuroscience, boosting their neurological pipeline. In a huge move, Sanofi also plans to invest at least $20 billion in US through 2030.
Sanofi News Analytics from Mon, 23 Sep 2024 12:06:18 GMT to Sat, 05 Jul 2025 07:05:09 GMT -
Rating 7
- Innovation 9
- Information 8
- Rumor -3
